T0	Participants 66 162	children, adolescents, and adults with mental retardation and pervasive developmental disorders.
T1	Participants 241 348	children, adolescents, and adults with mental retardation (MR) and pervasive developmental disorders (PDD).
T2	Participants 600 650	children, adolescents, and adults with MR and PDDs
T3	Participants 686 766	21-subject subset during the course of a double-blind, placebo-controlled trial.
T4	Participants 881 936	children and adolescents (n=10), mean age of 12.5 years
T5	Participants 1070 1100	adults, mean age of 35.3 years